Furthermore, the development of specific inhibitors or gene‐editing techniques to modulate c‐Fos/AP‐1 activity in liver cells should be explored to assess their therapeutic potential in liver dysfunction and cancer progression. The gene discussed is JUN; the disease is cancer.